About Aspivix
Aspivix is a company based in Lausanne (Switzerland) founded in 2015 by Mathieu Horras and Julien Elie Finci. Aspivix has raised $7.01 million across 9 funding rounds from investors including Zurcher Kantonalbank, European Union and Eureka Network. Aspivix offers products and services including Carevix. Aspivix operates in a competitive market with competitors including Daré Bioscience, Femasys, Adiana, Uteron Pharma and RemovAid, among others.
- Headquarter Lausanne, Switzerland
- Founders Mathieu Horras, Julien Elie Finci
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Aspivix Sa
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$7.01 M (USD)
in 9 rounds
-
Latest Funding Round
$5 M (USD), Series A
Nov 17, 2022
-
Investors
Zurcher Kantonalbank
& 8 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aspivix
Aspivix offers a comprehensive portfolio of products and services, including Carevix.
Suction-based tool to stabilize cervix and reduce pain in procedures
People of Aspivix
Unlock access to complete
Unlock access to complete
Funding Insights of Aspivix
Aspivix has successfully raised a total of $7.01M across 9 strategic funding rounds. The most recent funding activity was a Series A round of $5 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Aspivix
Aspivix has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Zurcher Kantonalbank, European Union and Eureka Network.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Regulatory affairs and marketing services are provided for healthcare entities.
|
Locked | Locked | Locked | |
|
Early stage investments in Swiss healthcare and technology are facilitated.
|
Locked | Locked | Locked | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked |
Investor details for Aspivix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Aspivix
Investment portfolio details for Aspivix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Aspivix
Detailed financials for Aspivix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Aspivix Comparisons
Peer comparison for Aspivix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Aspivix
Aspivix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Daré Bioscience, Femasys, Adiana, Uteron Pharma and RemovAid, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Non-hormonal pharmaceutical products for female contraceptives are developed.
|
|
| Locked | Locked | Locked |
Medical devices for women's healthcare are developed and provided.
|
|
| Locked | Locked | Locked |
Transcervical sterilization systems for permanent birth control are developed.
|
|
| Locked | Locked | Locked |
Develops products dedicated to female healthcare solutions.
|
|
| Locked | Locked | Locked |
Medical devices for subdermal implant removal are developed.
|
Detailed competitors of Aspivix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Aspivix
Complete news archive for Aspivix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aspivix
Aspivix was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Aspivix is headquartered in Lausanne, Switzerland. It is registered at Lausanne, Vaud, Switzerland.
Mathieu Horras is the current CEO of Aspivix. They have also founded this company.
Aspivix is a funded company, having raised a total of $7.01M across 9 funding rounds to date.
Aspivix was founded in 2015 in Lausanne, Switzerland, as a medtech company focused on gynecological devices. A suction-based tool called Carevix is developed to facilitate intrauterine contraceptive placement. The cervix is gently opened via vacuum application, minimizing pain and bleeding in procedures. Operations center on innovation in womens health solutions, with products targeted at clinical use in reproductive care settings.
Aspivix's top competitors include Daré Bioscience, Femasys and RemovAid.
Aspivix offers Carevix.
Aspivix has 9 investors. Key investors include Zurcher Kantonalbank, European Union, Eureka Network, Launchpad, and HEMEX.